CRISPR Therapeutics AG Stock News

Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (CRSP 1.46%), a mid-cap biotech, fits that description.

CRISPR Therapeutics' recent in vivo CTX310 data validates its technology, marking a fundamental shift and supporting a rating upgrade from Sell to Hold. CASGEVY sales are growing but remain unprofitable, with ex vivo therapy complexity limiting mass adoption and reinforcing the need for scalable in vivo solutions. Upcoming high-stakes clinical readouts for CTX310, CTX112, and CTX131 could signi...

Is this finally the year CRISPR Therapeutics (CRSP 6.33%) bounces back? The biotech has lagged the market in recent years, but shares are up 50% over the past three months and have climbed 42% since the start of 2025.

-CASGEVY ® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the program for strong future growth-

Biotechnology outfit CRISPR Therapeutics (CRSP -1.37%) isn't a name on many investors' radar -- and understandably so. Its market capitalization is a mere $6 billion.

Crispr Therapeutics AG stock has surged nearly 90% since my Buy call in early May, reaching its highest value since February 2024. The rally builds on the historic approval of Casgevy, a gene editing therapy for Sickle Cell Disease, developed with Vertex. Earlier concerns over slow Casgevy sales and lengthy patient hospital stays weighed heavily on the stock, which hit a five-year low in April.

Insider buying has been slow this month, as buy windows close ahead of the new earnings-reporting season.

Corporate insiders have taken a sharply pessimistic turn – selling their companies' shares at the fastest rate in at least a decade.